SIRT1 and lung cancer: Shin et al. (23) demonstrated that hypoxic inactivation of the SIRT1/5’ adenosine monophosphate-activated protein kinase (AMPK) pathway led to cisplatin and doxorubicin resistance, and a SIRT1 activator srt1720 could augment the antitumor effects of cisplatin, which was blocked by AMPK inhibitor compound C administration, suggesting the regulatory effect of SIRT1/AMPK on drug resistance in lung cancer under hypoxia.